About Sense Biodetection
Sense Biodetection is a company based in Abingdon (United Kingdom) founded in 2014 by Harry Lamble was acquired by Sherlock in February 2023. Sense Biodetection has raised $79.22 million across 6 funding rounds from investors including Gov.uk, Sherlock Biosciences and Mercia. The company has 43 employees as of June 30, 2021. Sense Biodetection offers products and services including Diagnostic Technologies and Innovation Pipeline. Sense Biodetection operates in a competitive market with competitors including GenMark Diagnostics, Stilla Technologies, Silicon Biosystems, NeuMoDx and Biomeme, among others.
- Headquarter Abingdon, United Kingdom
- Employees 43 as on 30 Jun, 2021
- Founders Harry Lamble
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sense Biodetection Limited
- Date of Incorporation 25 Jul, 2013
- Jurisdiction ABINGDON, ENGLAND
-
Annual Revenue
$14.24 K (USD)0as on Dec 31, 2022
-
Net Profit
-$36.38 M (USD)1as on Dec 31, 2023
-
EBITDA
-$38.72 M (USD)7as on Dec 31, 2023
-
Total Equity Funding
$79.22 M (USD)
in 6 rounds
-
Latest Funding Round
$15 M (USD), Series B
Nov 17, 2021
-
Investors
Gov.uk
& 7 more
-
Employee Count
43
as on Jun 30, 2021
-
Acquired by
Sherlock
(Feb 01, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sense Biodetection
Sense Biodetection offers a comprehensive portfolio of products and services, including Diagnostic Technologies and Innovation Pipeline.
Tools for bioscience testing and innovation purposes
Systems enhancing medical capabilities through acquisitions
People of Sense Biodetection
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Sense Biodetection
Sense Biodetection has successfully raised a total of $79.22M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $15.0M
-
First Round
First Round
(08 Jun 2016)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Series B - Sense Biodetection | Valuation | Koch Disruptive Technologies |
|
| Apr, 2021 | Amount | Series B - Sense Biodetection | Valuation | Koch Disruptive Technologies | |
| Oct, 2020 | Amount | Series B - Sense Biodetection | Valuation | Mercia , Cambridge Innovation Capital |
Investors in Sense Biodetection
Sense Biodetection has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Gov.uk, Sherlock Biosciences and Mercia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by the venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in life sciences and deep tech.
|
Founded Year | Domain | Location | |
|
Earlybird is recognized as a venture capital investor focused on early-stage tech companies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sense Biodetection
Financial Statements - Sense Biodetection
Sense Biodetection Comparisons
Competitors of Sense Biodetection
Sense Biodetection operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenMark Diagnostics, Stilla Technologies, Silicon Biosystems, NeuMoDx and Biomeme, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| domain | founded_year | HQ Location |
Digital PCR solutions for research are developed and analyzed.
|
|
| domain | founded_year | HQ Location |
Lab-on-a-chip technologies for miniaturized cell-biology testing are developed.
|
|
| domain | founded_year | HQ Location |
Developer of a platform for low cost molecular testing
|
|
| domain | founded_year | HQ Location |
Smartphone-based DNA detection platform is developed for diagnostics.
|
Frequently Asked Questions about Sense Biodetection
Sense Biodetection was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Sense Biodetection is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Sense Biodetection is a funded company, having raised a total of $79.22M across 6 funding rounds to date.
As of Jun 30, 2021, the latest employee count at Sense Biodetection is 43.
Annual revenue of Sense Biodetection is $14.24K as on Dec 31, 2022.
Sense Biodetection was founded in 2014 and is based in Abingdon, United Kingdom. Operations focus on the biotechnology sector, where proprietary molecular amplification and device technologies are utilized to enable sensitive detection of specific nucleic acids. Point-of-care diagnostic solutions are offered, supporting rapid molecular testing in clinical and field settings across various applications.
Sense Biodetection's top competitors include GenMark Diagnostics, Stilla Technologies and NeuMoDx.
Sense Biodetection offers Diagnostic Technologies and Innovation Pipeline.
Sense Biodetection has 8 investors. Key investors include Gov.uk, Sherlock Biosciences, Mercia, Koch Disruptive Technologies, and Cambridge Innovation Capital.